Confluent to Announce Second Quarter 2025 Financial Results on July 30, 2025
Video Webcast Information
Date: Wednesday, July 30, 2025
Time: 1:30 p.m. PT / 4:30 p.m. ET
Webcast: https://investors.confluent.io
Prior to the commencement of the webcast, Confluent's earnings press release and supplemental materials will be accessible from its investor relations website at investors.confluent.io. A replay of the webcast will also be accessible from Confluent's investor relations website a few hours after the conclusion of the live event.
About Confluent
Confluent is the data streaming platform that is pioneering a fundamentally new category of data infrastructure that sets data in motion. Confluent's cloud-native offering is the foundational platform for data in motion – designed to be the intelligent connective tissue enabling real-time data, from multiple sources, to constantly stream across the organization. With Confluent, organizations can meet the new business imperative of delivering rich, digital front-end customer experiences and transitioning to sophisticated, real-time, software-driven backend operations. To learn more, please visit www.confluent.io.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
$2,500 a night: FIFA demand sends Vancouver hotel prices sky high
The FIFA World Cup 2026 Vancouver logo is seen on the big screen at BC Place in this file photo. With nearly a year to go before Vancouver hosts 2026 FIFA World Cup matches, hotel rooms are already in short supply for the event, and far from affordable. CTV News compared prices for the weekend of the city's opening match, June 12 to 15, and found that most rooms with two beds in the downtown core are either fully booked or priced over $1,000 a night. ADVERTISEMENT We analyzed costs directly on hotel websites and on third-party sites like and Expedia. The Hyatt Regency has one ofthe more competitive options, with a two-bed room listed at $1,053 per night. A two-bed suite at the Century Plaza was $1,496, the OPUS Hotel was priced at $2,438, and Hotel Le Soleil came in at an even $2,500 per night. Even hotels outside the downtown core offered little relief. For example, a room at the Holiday Inn Vancouver-Centre in Fairview goes for $1,096. For comparison, rates at the same hotels drop dramatically by mid-August — two months after the FIFA matches. The Hyatt's price is roughly $500 lower, Century Plaza's drops by more than $1,000, and the OPUS rate is a fraction of its June price. We also noticed prices fluctuate frequently. Some rooms were suddenly a few hundred dollars cheaper (but still expensive) in the afternoon than they were in the morning. Some hotels might also offer more competitive options – for smaller rooms with a single bed – than are listed on third-party websites. Vancouver is set to host seven World Cup matches in 2026.
Globe and Mail
an hour ago
- Globe and Mail
EverGen Infrastructure Reports Q2 2025 Results
EverGen Infrastructure Corp. ('EverGen' or the 'Company') (TSXV: EVGN) (OTCQB: EVGIF), today reported financial results as at and for Q2 2025. All amounts are in Canadian dollars unless otherwise stated and have been prepared in accordance with IFRS. Strategic & Financing Updates $5 Million Private Placement: In May 2025, EverGen completed a $5 million non-brokered private placement of common shares with Ask America, LLC strengthening the Company's balance sheet. Debt Refinancing: The Company progressed refinancing of its Fraser Valley Biogas facility, with a signed letter of intent for a $13 million debt facility and $250,000 operating line of credit in February. EverGen expects to complete this refinancing in Q3 2025, with terms that are better aligned with the Company's current operations and strategic focus. Additional Equity Financing: Commitments and indications received for up to $2 million of additional proceeds pursuant to a second tranche of the private placement of common shares at a price of $0.60 per share. The Company has extended this tranche to close alongside the debt refinancing, anticipated in Q3 2025. In all other respects, the terms of the private placement and use of proceeds will remain as previously disclosed in the April 23, 2025, press release. The completion of the private placement is subject to customary closing conditions, including the approval of the TSX Venture Exchange (the "Exchange"). Operational Updates RNG Production Growth: RNG production increased 17% year-over-year setting a new quarterly record. In March and April 2025, FVB achieved over 12,000 gigajoules ('GJs') of monthly production and is now approaching a run-rate equal to the annual nameplate capacity of the facility of 160,000 GJ. Optimization Initiatives: With planned changes to senior leadership team complete, the Company initiated optimization activities across core facilities during Q2 2025. While these activities temporarily reduce incoming organic waste volumes and revenues, they are expected to unlock sustainable cash flow, future growth and underpin EverGen's position as a long-term RNG leader. Financial Results: Three months ended Jun 30, 2025 Jun 30, 2024 $ Change % Change FINANCIAL Revenue 2,781 4,238 (1,457) (34) Net loss (1,947) (875) (1,072) 123 Net loss per share ($), basic and diluted (0.10) (0.05) (0.05) 100 EBITDA (1) (822) 966 (1,788) (185) Adjusted EBITDA (1) 339 1,122 (783) (70) Total assets 78,577 93,828 (15,251) (16) Total long-term liabilities 25,657 29,321 (3,664) (12) Cash and cash equivalents and restricted cash 4,515 402 4,113 1,023 Working capital surplus (1) 1,449 994 455 46 COMMON SHARES (thousands) Outstanding, end of period 22,426 13,979 8,447 60 Weighted average – basic & diluted 17,762 13,947 3,815 27 OPERATING RNG (gigajoules) 49,297 42,219 7,078 17 Incoming organic feedstock (tonnes) 17,220 30,647 (13,427) (44) Organic compost and soil sales (yards) 5,303 11,742 (6,439) (55) Electricity (MWh) 853 911 (58) (6) (1)"EBITDA', "Adjusted EBITDA" and "Working capital surplus' do not have standardized meanings under IFRS Accounting Standards. Please refer to 'Non-GAAP Measures' below. Management Commentary 'Q2 2025 was a transformational quarter for EverGen as we successfully recapitalized the business, aligned our leadership with a supportive lead investor, and continued to deliver record RNG production,' said Chase Edgelow, CEO of EverGen. 'We're tracking well against our 100-day plan for the business, and while optimization activities will continue to impact near term revenues, these initiatives are critical to positioning EverGen for scalable growth in 2026 and beyond, reinforcing our long-term vision as Canada's leading RNG infrastructure platform.' Outlook With a stronger balance sheet, growing RNG output, and optimization initiatives underway, EverGen is positioned to deliver sustainable growth, enhance shareholder value, and advance its leadership in Canada's RNG sector. The Company expects to complete its refinancing and additional equity raise in Q3 2025, further strengthening its financial foundation. For further information on the results please see the Company's Consolidated Financial Statements and Management's Discussion and Analysis filed on SEDAR+ at and on EverGen's website at EverGen will hold a results and corporate update conference call at 11:00 a.m. Eastern Time on Friday, August 22, 2025, hosted by Chief Executive Officer, Chase Edgelow. Find the latest Corporate Presentation in the Investor Center: Market Maker Further, to support liquidity and trading of the Company's shares, EverGen has engaged Independent Trading Group ('ITG'), Inc. to assist in maintaining active and orderly trading in the market for the common shares of the Company on the TSX Venture Exchange (the "TSX-V"). The market-making service will be undertaken by ITG in compliance with the applicable policies of the TSX-V and other applicable laws. For its services, the Company has agreed to pay ITG a service fee of $6,000 with option to renew monthly. The Company and ITG act at arm's length. ITG, nor any of its principals, currently own any securities, directly or indirectly, of the Company. The engagement of ITG is subject to the Company making certain filings with the Exchange and acceptance by the Exchange. About EverGen Infrastructure Corp. EverGen, Canada's Renewable Natural Gas Infrastructure Platform, is combating climate change and helping communities contribute to a sustainable future. Headquartered on the West Coast of Canada, EverGen is an established independent renewable energy producer which acquires, develops, builds, owns, and operates a portfolio of Renewable Natural Gas, waste to energy, and related infrastructure projects. EverGen is focused on Canada, with continued growth expected across other regions in North America and beyond. For more information about EverGen Infrastructure Corp. and our projects, please visit Non-GAAP Measures EverGen uses certain financial measures referred to in this press release to quantify its results that are not prescribed by IFRS. The terms EBITDA, adjusted EBITDA and working capital are not recognized measures under IFRS and may not be comparable to that reported by other companies. EverGen believes that, in addition to measures prepared in accordance with IFRS, the non-IFRS measurement provide useful information to evaluate the Company's performance and ability to generate cash, profitability and meet financial commitments. These non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for other measures of performance prepared in accordance with IFRS. EBITDA is defined as net income (loss) before interest, tax and depreciation and amortization. Adjusted EBITDA is EBITDA adjusted for share-based payment expenses, unusual or non-recurring items, contingent consideration gains and losses and non-controlling interests in adjusted EBITDA. Working capital is calculated as current assets less current liabilities. Forward-Looking Information This news release contains certain forward-looking statements and/or forward-looking information (collectively, 'forward looking statements') within the meaning of applicable securities laws. When used in this release, such words as 'would', 'will', 'anticipates', 'believes', 'explores', 'expects' and similar expressions, as they relate to EverGen, or its management, are intended to identify such forward-looking statements. More particularly, and without limitation, this press release contains forward looking statements and information concerning the Company's expectations regarding revenue growth and future financial or operating performance and the completion of a debt refinancing and a second tranche of the private placement, including the timing and amounts thereof. Such forward-looking statements reflect the current views of EverGen with respect to future events, and are subject to certain risks, uncertainties and assumptions., including the receipt of all approvals and satisfaction of all conditions to completion of the debt refinancing and the extension and completion of the private placement and the acceptance by the Exchange of the engagement of ITG. Many factors could cause EverGen's actual results, performance or achievements to be materially different from any expected future results, performance or achievement that may be expressed or implied by such forward-looking statements and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits EverGen will derive therefrom, and accordingly, readers are cautioned not to put undue reliance on the forward-looking statements contained in this press release. The Company cautions that these forward-looking statements are subject to numerous risks and uncertainties, including but not limited to: counterparty risk to closing the debt refinancing and the second tranche of the private placement; the impact of general economic conditions in Canada, including the current inflationary environment; industry conditions including changes in laws and regulations and/or adoption of new environmental laws and regulations and changes in how they are interpreted and enforced, in Canada; volatility of prices for energy commodities; change in demand for clean energy to be offered by EverGen; competition; lack of availability of qualified personnel; obtaining required approvals of regulatory authorities in Canada; ability to access sufficient capital from internal and external sources; optimization and expansion of organic waste processing facilities and RNG feedstock; the realization of cost savings through synergies and efficiencies expected to be realized from the Company's completed acquisitions; the sufficiency of EverGen's liquidity to fund operations and to comply with covenants under its credit facility; continued growth through strategic acquisitions and consolidation opportunities; continued growth of the feedstock opportunity from municipal and commercial sources, and the factors discussed under 'Risk Factors' in the Company's Annual Information Form dated April 22, 2024, which is available on SEDAR+ at many of which are beyond the control of EverGen. Forward-looking statements included in this news release should not be read as guarantees of future performance or results. The forward-looking statements contained in this release are made as of the date of this release, and except as may be expressly required by applicable law, EverGen disclaims any intent, obligation or undertaking to publicly release any updates or revisions to any forward-looking statements contained herein whether as a result of new information, future events or results or otherwise. This news release shall not constitute an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction.
Globe and Mail
2 hours ago
- Globe and Mail
Migraine Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
DelveInsight's, 'Migraine Pipeline Insight 2025' report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Migraine Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Migraine Treatment Landscape. Click here to read more @ Migraine Pipeline Outlook Key Takeaways from the Migraine Pipeline Report On 17 August 2025, Teva Branded Pharmaceutical Products R&D LLC announced a study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). On 15 August 2025, Pfizer conducted a study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue. On 15 August 2025, AbbVie announced a study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. The study will include 2 cohorts of participants - PK Cohort and Main Study (non-PK cohort) DelveInsight's Migraine pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Migraine treatment. The leading Migraine Companies such as Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others. Promising Migraine Pipeline Therapies such as ALD403 (Eptinezumab), Ketorolac, Sumatriptan, divalproex sodium, Erenumab, GSK1838262, ALD403 and others. Stay informed about the cutting-edge advancements in Migraine Treatments. Download for updates and be a part of the revolution in Neurology care @ Migraine Clinical Trials Assessment Migraine Emerging Drugs Profile AXS-07: Axsome Therapeutics AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-07 is thought to act by inhibiting Calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation, and inhibiting neuroinflammation, pain signal transmission, and central sensitization. Meloxicam is a new molecular entity for migraine enabled by MoSEIC™ technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life. AXS-07 is currently being developed for the acute treatment of migraine. The product is in the NDA submitted phase of development. STS-101: Satsuma Pharmaceuticals STS101 combines the Satsuma powder technology with an easy-to-use nasal delivery device to create a reliable and convenient DHE product potentially able to provide the unique clinical advantages of DHE while overcoming the shortcomings of existing DHE products. TS101 has a number of key advantages that we believe may provide significant benefits over other acute treatments for migraine and result in robust and consistent clinical performance. These advantages arise from our proprietary dry-powder formulation, which incorporates a mucoadhesive drug carrier and engineered drug particle technologies, and our proprietary nasal delivery device. STS101 is an investigational product that is currently being evaluated in Phase 3 clinical trials for the acute treatment of migraine and is not approved by the U.S. Food and Drug Administration. Zavegepant: Biohaven Pharmaceuticals Zavegepant (BHV-3500) is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist. The chemical properties of zavegepant make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral is currently in Phase III stage of development for Migraine and is being developed by Biohaven Pharmaceuticals. TNX1900: Tonix Pharmaceuticals TNX-1900(Oxytocin), Tonix's proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage and is currently being studied as a candidate for prophylaxis of chronic migraine. Oxytocin is a naturally occurring human hormone that acts as a neurotransmitter in the brain. In clinical and preliminary research, it has been observed that increased oxytocin levels can relieve headaches. When oxytocin is delivered via the nasal route, it results in enhanced binding to receptors on neurons in the trigeminal system, inhibiting transmission of pain signals. Intranasal oxytocin has been well tolerated in several clinical trials in adults and children and has been shown to block calcitonin gene-related peptide (CGRP) release in animals, a pathway known to be critical to the pathogenesis of migraine attacks. TNX-1900 is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP. TNX-1900 is an investigational new drug and has not been approved for any indication. The Migraine pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment. Migraine Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market. Get a detailed analysis of the latest innovations in the Migraine pipeline. Explore DelveInsight's expert-driven report today! @ Migraine Unmet Needs Migraine Companies Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others. Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Ophthalmic Oral Parenteral Subcutaneous Topical Transdermal Migraine Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Discover the latest advancements in Migraine Treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Migraine Market Drivers and Barriers, and Future Perspectives Scope of the Migraine Pipeline Report Coverage- Global Migraine Companies- Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others. Migraine Pipeline Therapies- ALD403 (Eptinezumab), Ketorolac, Sumatriptan, divalproex sodium, Erenumab, GSK1838262, ALD403 and others. Migraine Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Migraine Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Migraine Pipeline on our website @ Migraine Emerging Drugs and Companies Table of Content Introduction Executive Summary Migraine: Overview Pipeline Therapeutics Therapeutic Assessment Migraine– DelveInsight's Analytical Perspective Late Stage Products (Pre-Registration) AXS-07: Axsome Therapeutics Drug profiles in the detailed report….. Last Stage Products (Phase III) STS-101: Satsuma Pharmaceuticals Drug profiles in the detailed report….. Mid Stage Products (Phase II) TNX1900: Tonix Pharmaceuticals Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company Name Drug profiles in the detailed report….. Inactive Products Migraine Key Companies Migraine Key Products Migraine - Unmet Needs Migraine - Market Drivers and Barriers Migraine - Future Perspectives and Conclusion Migraine Analyst Views Migraine Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
